Clinical trial
Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's…
NCT00044551 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00044551 |
|---|---|
| Title | Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma |
| Official title | An Open Phase II, Multi Center Trial of BAY 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin |
| Intervention type | Drug |
| Interventions | Taxane (Cytotoxic, BAY59-8862) |
| Enrollment | 29 |
| Start date | Feb 1, 2002 |
| Completion | Jul 1, 2003 |
| First posted | Sep 4, 2002 |
| Last update posted | Oct 14, 2013 |
| Countries | Canada, France, Germany, Netherlands, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: